Summary
Global Markets Direct’s, ‘Smallpox - Pipeline Review, H2 2016’, provides an overview of the Smallpox pipeline landscape.
The report provides comprehensive information on the therapeutics under development for Smallpox, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Smallpox and features dormant and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.
Scope
- The report provides a snapshot of the global therapeutic landscape of Smallpox
- The report reviews pipeline therapeutics for Smallpox by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Smallpox therapeutics and enlists all their major and minor projects
- The report assesses Smallpox therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Smallpox
Reasons to buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Smallpox
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Smallpox pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Companies Mentioned
Bavarian Nordic A/S
BioFactura, Inc.
CEL-SCI Corporation
Chimerix, Inc.
CJ HealthCare Corp.
EpiVax, Inc.
SIGA Technologies, Inc.
Takeda Pharmaceutical Company Limited
Tonix Pharmaceuticals Holding Corp.
'
Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
Smallpox Overview 7
Therapeutics Development 8
Pipeline Products for Smallpox - Overview 8
Pipeline Products for Smallpox - Comparative Analysis 9
Smallpox - Therapeutics under Development by Companies 10
Smallpox - Therapeutics under Investigation by Universities/Institutes 11
Smallpox - Pipeline Products Glance 12
Late Stage Products 12
Early Stage Products 13
Smallpox - Products under Development by Companies 14
Smallpox - Products under Investigation by Universities/Institutes 15
Smallpox - Companies Involved in Therapeutics Development 16
Bavarian Nordic A/S 16
BioFactura, Inc. 17
CEL-SCI Corporation 18
Chimerix, Inc. 19
CJ HealthCare Corp. 20
EpiVax, Inc. 21
SIGA Technologies, Inc. 22
Takeda Pharmaceutical Company Limited 23
Tonix Pharmaceuticals Holding Corp. 24
Smallpox - Therapeutics Assessment 25
Assessment by Monotherapy Products 25
Assessment by Combination Products 26
Assessment by Target 27
Assessment by Mechanism of Action 29
Assessment by Route of Administration 31
Assessment by Molecule Type 33
Drug Profiles 35
(plague + small pox) vaccine - Drug Profile 35
Product Description 35
Mechanism Of Action 35
R&D Progress 35
24a - Drug Profile 36
Product Description 36
Mechanism Of Action 36
R&D Progress 36
brincidofovir - Drug Profile 37
Product Description 37
Mechanism Of Action 37
R&D Progress 37
CEL-1000 - Drug Profile 50
Product Description 50
Mechanism Of Action 50
R&D Progress 50
CJ-40011 - Drug Profile 52
Product Description 52
Mechanism Of Action 52
R&D Progress 52
imatinib mesylate - Drug Profile 53
Product Description 53
Mechanism Of Action 53
R&D Progress 53
Monoclonal Antibodies for Infectious Disease - Drug Profile 54
Product Description 54
Mechanism Of Action 54
R&D Progress 54
Monoclonal Antibody for Smallpox - Drug Profile 55
Product Description 55
Mechanism Of Action 55
R&D Progress 55
nilotinib - Drug Profile 56
Product Description 56
Mechanism Of Action 56
R&D Progress 56
PL-801 - Drug Profile 57
Product Description 57
Mechanism Of Action 57
R&D Progress 57
SCV-305 - Drug Profile 58
Product Description 58
Mechanism Of Action 58
R&D Progress 58
small pox vaccine - Drug Profile 59
Product Description 59
Mechanism Of Action 59
R&D Progress 59
smallpox vaccine - Drug Profile 60
Product Description 60
Mechanism Of Action 60
R&D Progress 60
smallpox vaccine - Drug Profile 64
Product Description 64
Mechanism Of Action 64
R&D Progress 64
tecovirimat - Drug Profile 65
Product Description 65
Mechanism Of Action 65
R&D Progress 65
VIR-002 - Drug Profile 70
Product Description 70
Mechanism Of Action 70
R&D Progress 70
Smallpox - Dormant Projects 71
Smallpox - Discontinued Products 73
Smallpox - Product Development Milestones 74
Featured News & Press Releases 74
Jun 15, 2016: Bavarian Nordic Announces Expansion of IMVAMUNE Orders from Canadian Government 74
Feb 24, 2016: FDA Concurs on Clinical Dose for SIGA’s Tecovirimat Antiviral 74
Feb 08, 2016: Chimerix Presents Positive Results From Brincidofovir Pivotal Study in Animal Model for Smallpox 74
Dec 24, 2015: Delaware Supreme Court Affirms Chancery Court Ruling in Favor of PharmAthene 75
Sep 14, 2015: Chimerix and BARDA Announce Contract Extension of $13.0 Million for the Continued Development of Brincidofovir for Smallpox 75
Jul 23, 2015: Chimerix Announces Positive Topline Results From Brincidofovir Pivotal Study in Animal Model for Smallpox 76
Jul 07, 2015: Bavarian Nordic Receives Order for IMVAMUNE Smallpox Vaccine from the U.S. Government Valued at USD 133 Million 76
May 13, 2015: Bavarian Nordic Announces Positive Results from Two Pivotal Clinical Studies of IMVAMUNE Smallpox Vaccine 77
Jan 16, 2015: SIGA Technologies Appeals Judgment of Delaware Court of Chancery 78
Jan 07, 2015: Delaware Court of Chancery Issues Order Specifying Amount Of Lump Sum Expectation Damages Payable To PharmAthene; Total Award When Finalized, Including Pre-Judgment Interest, Attorneys' And Expert Witness Fees, Estimated To Be In Excess Of $190 Million 78
Dec 23, 2014: Chimerix Provides Recap of 2014 Events 79
Oct 04, 2014: Bavarian Nordic Announces Exercise of Contract Option by the U.S. Government for Continued Supply of IMVAMUNE Smallpox Vaccine 80
Sep 04, 2014: Bavarian Nordic Announces Exercise Of Contract Option By The U.S. Government For Continued Supply Of Imvamune Smallpox Vaccine 80
Sep 02, 2014: Chimerix and BARDA Announce Continued Partnership in the Development of Brincidofovir for Smallpox 81
Aug 26, 2014: Bavarian Nordic Receives Order from the Canadian Government to Supply IMVAMUNE Smallpox Vaccine 81
Appendix 83
Methodology 83
Coverage 83
Secondary Research 83
Primary Research 83
Expert Panel Validation 83
Contact Us 83
Disclaimer 84
List of Tables
Number of Products under Development for Smallpox, H2 2016 8
Number of Products under Development for Smallpox - Comparative Analysis, H2 2016 9
Number of Products under Development by Companies, H2 2016 10
Number of Products under Investigation by Universities/Institutes, H2 2016 11
Comparative Analysis by Late Stage Development, H2 2016 12
Comparative Analysis by Early Stage Development, H2 2016 13
Products under Development by Companies, H2 2016 14
Products under Investigation by Universities/Institutes, H2 2016 15
Smallpox - Pipeline by Bavarian Nordic A/S, H2 2016 16
Smallpox - Pipeline by BioFactura, Inc., H2 2016 17
Smallpox - Pipeline by CEL-SCI Corporation, H2 2016 18
Smallpox - Pipeline by Chimerix, Inc., H2 2016 19
Smallpox - Pipeline by CJ HealthCare Corp., H2 2016 20
Smallpox - Pipeline by EpiVax, Inc., H2 2016 21
Smallpox - Pipeline by SIGA Technologies, Inc., H2 2016 22
Smallpox - Pipeline by Takeda Pharmaceutical Company Limited, H2 2016 23
Smallpox - Pipeline by Tonix Pharmaceuticals Holding Corp., H2 2016 24
Assessment by Monotherapy Products, H2 2016 25
Assessment by Combination Products, H2 2016 26
Number of Products by Stage and Target, H2 2016 28
Number of Products by Stage and Mechanism of Action, H2 2016 30
Number of Products by Stage and Route of Administration, H2 2016 32
Number of Products by Stage and Molecule Type, H2 2016 34
Smallpox - Dormant Projects, H2 2016 71
Smallpox - Dormant Projects (Contd..1), H2 2016 72
Smallpox - Discontinued Products, H2 2016 73
List of Figures
Number of Products under Development for Smallpox, H2 2016 8
Number of Products under Development for Smallpox - Comparative Analysis, H2 2016 9
Number of Products under Development by Companies, H2 2016 10
Comparative Analysis by Early Stage Products, H2 2016 13
Assessment by Monotherapy Products, H2 2016 25
Number of Products by Targets, H2 2016 27
Number of Products by Stage and Targets, H2 2016 27
Number of Products by Mechanism of Actions, H2 2016 29
Number of Products by Stage and Mechanism of Actions, H2 2016 29
Number of Products by Routes of Administration, H2 2016 31
Number of Products by Stage and Routes of Administration, H2 2016 31
Number of Products by Molecule Types, H2 2016 33
Number of Products by Stage and Molecule Types, H2 2016 33
